<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medalphabet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский алфавит</journal-title><trans-title-group xml:lang="en"><trans-title>Medical alphabet</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-5631</issn><issn pub-type="epub">2949-2807</issn><publisher><publisher-name>ООО «Альфмед»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33667/2078-5631-2021-19-64-72</article-id><article-id custom-type="elpub" pub-id-type="custom">medalphabet-2137</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Роль омега-3 жирных кислот в парентеральном питании онкологических больных</article-title><trans-title-group xml:lang="en"><trans-title>Role of omega-3 fatty acids in parenteral nutrition of cancer patients</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8509-4338</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гамеева</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gameeva</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гамеева Елена Владимировна, к.м.н., зам. директора по лечебной работе</p><p>Москва</p></bio><bio xml:lang="en"><p>Gameeva Elena V., PhD Med, deputy. Director of Clinical Work</p><p>Moscow</p><p> </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5278-7058</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шестопалов</surname><given-names>А. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Shestopalov</surname><given-names>A. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шестопалов Александр Ефимович, д.м.н., профессор, проф. кафедры анестезиологии и неотложной медицины, главный научный сотрудник</p><p>Москва</p><p>Московская область, с/п Соколовское, д. Лыткино</p></bio><bio xml:lang="en"><p>Shestopalov Alexander E., MD, professor, prof. Department of Anesthesiology and Emergency Medicine, Chief Researcher</p><p>Moscow</p><p>Lytkino, Moscow Region</p></bio><email xlink:type="simple">ashest@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Московский научно-исследовательский онкологический институт имени П. А. Герцена – филиал ФГБУ «Национальный&#13;
медицинский исследовательский радиологический центр» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Research Institute n.a. P. A. Herzen – a Branch of the National Medical Radiological Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ДПО «Российская медицинская академия непрерывного последипломного образования» Минздрава России; ФГБНУ «Федеральный научно-клинический центр реаниматологии и реабилитологии»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian Medical Academy for Postgraduate Continuous Education; Federal Scientifi and Clinical Centrе fоr Reanimatology and Rehabilitation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>18</day><month>08</month><year>2021</year></pub-date><volume>0</volume><issue>19</issue><issue-title>Диагностика и онкотерапия (2)</issue-title><fpage>64</fpage><lpage>72</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Гамеева Е.В., Шестопалов А.Е., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Гамеева Е.В., Шестопалов А.Е.</copyright-holder><copyright-holder xml:lang="en">Gameeva E.V., Shestopalov A.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-alphabet.com/jour/article/view/2137">https://www.med-alphabet.com/jour/article/view/2137</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. При подборе компонентов парентерального питания (ПП) для пациентов онкологического профиля необходимо учитывать не только оптимизацию состава, но и возможность положительного влияния на исход хирургического лечения. С этих позиций большой теоретический и практический интерес представляет применение в ПП фармаконутриентов, в частности омега-3 жирных кислот рыбьего жира, что и определило цель данного исследования.</p></sec><sec><title>Цель исследования</title><p>Цель исследования. Оценить возможности полноценного обеспечения энергопластических потребностей и разрешения метаболических нарушений в послеоперационном периоде у онкологических больных с новообразованиями желудка и кишки путем применения системы парентерального питания «три-в-одном», включающей омега-3 жирные кислоты.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Исследование проспективное выполнено у 58 пациентов, перенесших оперативное вмешательство по поводу рака желудка и кишки, рандомизированных на две группы. 1 -я группа сравнения – 29 пациентов, послеоперационное ПП осуществляли с использованием системы «три-в-одном» без омега-3 ЖК в составе; 2-я группа основная – 20 пациентов – получали ПП с омега-3 ЖК в составе в центральную вену (СМОФКабивен центральный), 9 –ПП с омега-3 ЖК в периферическую вену (СМОФКабивен периферический).</p></sec><sec><title>Основные результаты</title><p>Основные результаты. Полный спектр аминокислот, входящих в состав СМОФКабивен (50 г/л), повышенное содержание азота – 8 г/л оказывают выраженное влияние на метаболизм белков и процессы анаболизма. В основной группе печеночные пробы (аланинтрансаминаза [ALT], аспартаттрансаминаза [AST], и общий билирубин) были значимо ниже, чем у пациентов в группе сравнения. Полученные результаты свидетельствуют о том, что у больных 2-й группы к 6–7-м суткам послеоперационного периода на фоне парентерального питания с включением омега-3 ЖК концентрация провоспалительных цитокинов (IL-6–79,5 ± 19,2 пг/мл; TNF-α – 12,9 ± 3,3 пг/мл) достоверно (р &lt;0,05) ниже, чем в 1 -й группе. Клинические признаки дисфункции ЖКТ в основном разрешались на 4–5-е сутки. Функции ЖКТ полностью восстанавливались более чем у 80 % больных. Противовоспалительные свойства омега-3 ЖК, а также их влияние на восстановление баланса цитокинов в наших исследованиях подтверждены достоверными снижениями синтеза IL-6, ФНО.</p></sec><sec><title>Заключение</title><p>Заключение. Высокое содержание омега-3 ЖК в составе ПП оказывает позитивное влияние на разрешение метаболических нарушений в ранние сроки после оперативных вмешательств, возможность адекватно переносить ПХТ и лучевую терапию, а также на качество жизни в условиях прогрессирующего заболевания.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Relevance</title><p>Relevance. When selecting the components of parenteral nutrition (PN) for oncology patients, it is necessary to take into account not only the composition optimization but also its potential positive effect on the surgical treatment outcome. Therefore, the use of pharmaconutrients in PN, in particular, omega-3 fatty acids, is of great theoretical and practical interest and has determined the aim of this study.</p></sec><sec><title>The aim</title><p>The aim. To assess the effiacy of postoperative PN using the 3-in-1 system with omega-3 fatty acids (FA) (SMOFKabiven central and peripheral) in the treatment of metabolic disorders in patients undergoing gastrointestinal cancer surgery.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. A prospective, randomized, controlled, comparative study included the patients undergoing gastrointestinal cancer surgery. Group 1 (comparison group) consisted of 29 patients, postoperative PN was performed using a 3-in-1 system without omega-3 fatty acids.</p><p>Group 2 (main group) consisted of 20 patients treated with 3-in-1 system with omega-3 FA (SMOFKabiven central) and 9 patients recieved PN with omega-3 FA through peripheral vein access FA (SMOFKabiven peripheral).</p></sec><sec><title>Main results</title><p>Main results. A complete range of amino acids in SMOFKabiven (50 g/L) and an increased content of nitrogen (8 g/L) have a pronounced effect on protein metabolism and anabolic processes. The long-term PN showed that the liver enzyme (alanine transaminase [ALT], aspartate transaminase [AST], and total bilirubin) levels were signifiantly lower compared to the patients who received traditional lipid emulsions without fih oil. The analysis of the corrective effect of PN containing omega-3 fatty acids showed that at day 6–7 after surgery the group 2 patients had a signifiant decrease in the concentration of pro-inflmmatory cytokines: IL-6 down to 79.5±19.2 pg/mL, TNF-α down to 12.9±3.3 pg/mL (p &lt; 0.05) compared to group 1. Clinical signs of gastrointestinal dysfunction were mainly resolved at day 4–5. Full recovery of the GIT functions was seen in more than 80 % of patients. The anti-inflmmatory properties of omega-3 fatty acids, as well as their effect on the cytokine balance recovery, have been confimed in our studies by signifiant reductions in the synthesis of IL-6, TNF.</p></sec><sec><title>Conclusion</title><p>Conclusion. The high content of omega-3 fatty acids in PN promotes early management of metabolic disorders after surgery, can have a signifiant effect on the ability to adequately tolerate the maintenance chemotherapy and radiation therapy, and can signifiantly improve the quality of life under the conditions of progressive disease.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>пациенты онкологического профиля в послеоперационном периоде</kwd><kwd>парентеральное питание</kwd><kwd>омега‑3 жирные кислоты</kwd><kwd>рыбий жир.</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cancer patients postoperatively</kwd><kwd>parenteral nutrition</kwd><kwd>omega‑3 fatty acids from fih oil</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">А. В. Снеговой. Раннее энтерально-зондовое питание после операций у больных раком желудка. Дисс. к. м.н. М., 2004, 119 с.</mixed-citation><mixed-citation xml:lang="en">A. V. Snegovoy. Early enteral nutrition in gastric cancer patients after surgery. Thesis for a Candidate Degree in Medical Sciences. M., 2004, 119 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">А. И. Салтанов, В. Ю. Сельчук, А. В. Снеговой. Основы нутритивной поддержки в онкологической клинике. Москва, 2009, 239 с.</mixed-citation><mixed-citation xml:lang="en">А. I. Saltanov, V. Yu. Selchuk, A. V. Snegovoy. Fundamentals of nutritional support in oncology clinic. Moscow, 2009, 239 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">А. И. Салтанов, И. Н. Лейдерман, А. В. Снеговой. Искусственное питание в поддерживающей терапии онкологических больных. Москва, 2012, 406 с.</mixed-citation><mixed-citation xml:lang="en">А. I. Saltanov, I. N. Leyderman, A. V. Snegovoy. Nutritional support in the maintenance therapy of cancer patients. Moscow, 2012, 406 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">ESPEN guidelines on nutrition in cancer patients. Jann Arends, Patrick Bachmann, Vickie Baracos et al. Clinical Nutrition, 36 (2017) 11–48.</mixed-citation><mixed-citation xml:lang="en">ESPEN guidelines on nutrition in cancer patients. Jann Arends, Patrick Bachmann, Vickie Baracos et al. Clinical Nutrition, 36 (2017) 11–48.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Tsoli M, Robertson G. Cancer cachexia: malignant inflmmation, tumorkines, and metabolic mayhem. Trends Endocrinol Metab 2013; 24 (4): 174–83.</mixed-citation><mixed-citation xml:lang="en">Tsoli M, Robertson G. Cancer cachexia: malignant inflmmation, tumorkines, and metabolic mayhem. Trends Endocrinol Metab 2013; 24 (4): 174–83.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bing C. Lipid mobilization in cachexia: mechanisms and mediators. Curr Opin Support Palliat Care 2011; 5 (4): 356–60.</mixed-citation><mixed-citation xml:lang="en">Bing C. Lipid mobilization in cachexia: mechanisms and mediators. Curr Opin Support Palliat Care 2011; 5 (4): 356–60.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Singer P., Blaser A. R., Berger M. M. ESPEN guideline on clinical nutrition in the intensive care unit. Clin. Nutr. 2019 (38): 48–79.</mixed-citation><mixed-citation xml:lang="en">Singer P., Blaser A. R., Berger M. M. ESPEN guideline on clinical nutrition in the intensive care unit. Clin. Nutr. 2019 (38): 48–79.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lim SL, Ong KC, Chan YH, Loke WC, Ferguson M, Daniels L. Malnutrition and its impact on cost of hospitalization, length of stay, readmission and 3-year mortality. Clin Nutr. 2012 Jun; 31 (3): 345–50. DOI: 10.1016/j.clnu.2011.11.001. Epub 2011 Nov 26.</mixed-citation><mixed-citation xml:lang="en">Lim SL, Ong KC, Chan YH, Loke WC, Ferguson M, Daniels L. Malnutrition and its impact on cost of hospitalization, length of stay, readmission and 3-year mortality. Clin Nutr. 2012 Jun; 31 (3): 345–50. DOI: 10.1016/j.clnu.2011.11.001. Epub 2011 Nov 26.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Арыкан Н. Г., Шестопалов А. Е., Митичкин А. Е., Варнавин О. А., Васин В. С., Лапин В. А., Каюпова Г. Ф. Цели нутритивной поддержки в предоперационном периоде. РМЖ 2019 (7): 22–25.</mixed-citation><mixed-citation xml:lang="en">Arykan N. G., Shestopalov A. E., Mitichkin A. E. , Varnavin O. A., Vasin V. S., Lapin V. A., Kaupova G. F. Goals of nutritional support in the preoperative period. BC 2019 (7): 22–25(In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Сергиенко А. Д. Влияние нутритивной терапии на показатели качества жизни больных раком желудка на этапе хирургического лечения. Сергиенко А. Д., Хороненко В. Э., Гамеева Е. В., Рябов А. Б., Хомяков В. М. Исследования и практика в медицине 2019. Т. 6. № 3. С. 108–114.</mixed-citation><mixed-citation xml:lang="en">Sergienko A. D. , Khoronenko V. E. , Gameeva E. V. , Ryabov A. B. , Khomyakov V. M. Inflence of nutritive therapy on indicators of the quality of life of patients with gastric cancer at the stage of surgical treatment. Sergienko A. D., Khoronenko V. E., Gameeva E. V., Ryabov A. B., Khomyakov V. M. Research and practice in medicine 2019. Vol. 6. No. 3. pp. 108–114. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Yoon S. L., Kim J. A., Kelly D. L., D. Lyon, T. J George Jr. Predicting unintentional weight loss in patients with gastrointestinal cancer. J Cachexia Sarcopenia Muscle. 2019. Vol. 10. No. 3. p. 526–535.</mixed-citation><mixed-citation xml:lang="en">Yoon S. L., Kim J. A., Kelly D. L., D. Lyon, T. J George Jr. Predicting unintentional weight loss in patients with gastrointestinal cancer. J Cachexia Sarcopenia Muscle. 2019. Vol. 10. No. 3. p. 526–535.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Pressoir M, Desne S, Berchery D, Rossignol G, Poiree B, Meslier M, et al. Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres. Br J Cancer 2010; 102 (6): 966–71.</mixed-citation><mixed-citation xml:lang="en">Pressoir M, Desne S, Berchery D, Rossignol G, Poiree B, Meslier M, et al. Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres. Br J Cancer 2010; 102 (6): 966–71.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Wie GA, Cho YA, Kim SY, Kim SM, Bae JM, Joung H. Prevalence and risk factors of malnutrition among cancer patients according to tumor location and stage in the National Cancer Center in Korea. Nutrition 2010; 26 (3): 263–8.</mixed-citation><mixed-citation xml:lang="en">Wie GA, Cho YA, Kim SY, Kim SM, Bae JM, Joung H. Prevalence and risk factors of malnutrition among cancer patients according to tumor location and stage in the National Cancer Center in Korea. Nutrition 2010; 26 (3): 263–8.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Sesterhenn AM, Szalay A, Zimmermann AP, Werner JA, Barth PJ, Wiegand S. [Signifiance of autopsy in patients with head and neck cancer]. Laryngorhinootologie 2012; 91 (6): 375–80.</mixed-citation><mixed-citation xml:lang="en">Sesterhenn AM, Szalay A, Zimmermann AP, Werner JA, Barth PJ, Wiegand S. [Signifiance of autopsy in patients with head and neck cancer]. Laryngorhinootologie 2012; 91 (6): 375–80.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Нebuterne X, Lemarie E, Michallet M, de Montreuil CB, Schneider SM, Goldwasser F. Prevalence of malnutrition and current use of nutrition support in patients with cancer. J Parenter Enteral Nutr 2014; 38 (2): 196–204.</mixed-citation><mixed-citation xml:lang="en">Нebuterne X, Lemarie E, Michallet M, de Montreuil CB, Schneider SM, Goldwasser F. Prevalence of malnutrition and current use of nutrition support in patients with cancer. J Parenter Enteral Nutr 2014; 38 (2): 196–204.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Planas M, Alvarez-Hernandez J, Leon-Sanz M, Celaya-Perez S, Araujo K, Garcia de Lorenzo A. Prevalence of hospital malnutrition in cancer patients: a sub-analysis of the PREDyCES study. Support Care Cancer 2016; 24 (1): 429–35.</mixed-citation><mixed-citation xml:lang="en">Planas M, Alvarez-Hernandez J, Leon-Sanz M, Celaya-Perez S, Araujo K, Garcia de Lorenzo A. Prevalence of hospital malnutrition in cancer patients: a sub-analysis of the PREDyCES study. Support Care Cancer 2016; 24 (1): 429–35.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, MH Cohen, HO Douglass Jr, PF Engstrom, EZ Ezdinli, J Horton, GJ Johnson, CG Moertel, MM Oken, CPerlia, C Rosenbaum, MN Silverstein, RT Skeel, RW Sponzo, DC Tormey. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980; 69 (4): 491–7.</mixed-citation><mixed-citation xml:lang="en">Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, MH Cohen, HO Douglass Jr, PF Engstrom, EZ Ezdinli, J Horton, GJ Johnson, CG Moertel, MM Oken, CPerlia, C Rosenbaum, MN Silverstein, RT Skeel, RW Sponzo, DC Tormey. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980; 69 (4): 491–7.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Silva FR, de Oliveira MG, Souza AS, Figueroa JN, Santos CS. Factors associated with malnutrition in hospitalized cancer patients: a cross-sectional study. Nutr J 2015; 14: 123.</mixed-citation><mixed-citation xml:lang="en">Silva FR, de Oliveira MG, Souza AS, Figueroa JN, Santos CS. Factors associated with malnutrition in hospitalized cancer patients: a cross-sectional study. Nutr J 2015; 14: 123.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Pierre Singer, Annika Reintam Blaser, Mette M. Berger. ESPEN guideline on clinical nutrition in the intensive care unit. Volume 38, Issue 1, P. 48–79, February 01, 2019. Published: September 29, 2018. DOI: https://doi.org/10.1016/j.clnu.2018.08.037.</mixed-citation><mixed-citation xml:lang="en">Pierre Singer, Annika Reintam Blaser, Mette M. Berger. ESPEN guideline on clinical nutrition in the intensive care unit. Volume 38, Issue 1, P. 48–79, February 01, 2019. Published: September 29, 2018. DOI: https://doi.org/10.1016/j.clnu.2018.08.037.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Roxburgh CS, McMillan DC. Cancer and systemic inflmmation: treat the tumour and treat the host. Br J Cancer 2014; 110 (6): 1409–12.</mixed-citation><mixed-citation xml:lang="en">Roxburgh CS, McMillan DC. Cancer and systemic inflmmation: treat the tumour and treat the host. Br J Cancer 2014; 110 (6): 1409–12.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Laird BJ, Fallon M, Hjermstad MJ, Tuck S, Kaasa S, Klepstad P, D. C McMillan. Quality of life in patients with advanced cancer: differential association with performance status and systemic inflmmatory response. J Clin Oncol 2016; 34 (23): 2769–75.</mixed-citation><mixed-citation xml:lang="en">Laird BJ, Fallon M, Hjermstad MJ, Tuck S, Kaasa S, Klepstad P, D. C McMillan. Quality of life in patients with advanced cancer: differential association with performance status and systemic inflmmatory response. J Clin Oncol 2016; 34 (23): 2769–75.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Laird BJ, Kaasa S, McMillan DC, Fallon MT, Hjermstad MJ, Fayers P, P. Klepstad. Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflmmation-based prognostic system. Clin Cancer Res 2013; 19 (19): 5456–64.</mixed-citation><mixed-citation xml:lang="en">Laird BJ, Kaasa S, McMillan DC, Fallon MT, Hjermstad MJ, Fayers P, P. Klepstad. Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflmmation-based prognostic system. Clin Cancer Res 2013; 19 (19): 5456–64.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">McMillan DC. The systemic inflmmation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 2013; 39 (5): 534–40.</mixed-citation><mixed-citation xml:lang="en">McMillan DC. The systemic inflmmation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 2013; 39 (5): 534–40.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Dantzer R. Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur J Рharmacol 2004; 500 (1–3): 399–411.</mixed-citation><mixed-citation xml:lang="en">Dantzer R. Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur J Рharmacol 2004; 500 (1–3): 399–411.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Costa MD, Vieira de Melo CY, Amorim AC, Cipriano Torres Dde O, Dos Santos AC. Association between nutritional status, inflmmatory condition, and prognostic indexes with postoperative complications and clinical outcome of patients with gastrointestinal neoplasia. Nutr Cancer 2016; 68 (7): 1108–14.</mixed-citation><mixed-citation xml:lang="en">Costa MD, Vieira de Melo CY, Amorim AC, Cipriano Torres Dde O, Dos Santos AC. Association between nutritional status, inflmmatory condition, and prognostic indexes with postoperative complications and clinical outcome of patients with gastrointestinal neoplasia. Nutr Cancer 2016; 68 (7): 1108–14.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Ryan AM, Power DG, Daly L, Cushen SJ, Ni Bhuachalla E, Prado CM. Cancerassociated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later. Proc Nutr Soc 2016; 75 (2): 199–211.</mixed-citation><mixed-citation xml:lang="en">Ryan AM, Power DG, Daly L, Cushen SJ, Ni Bhuachalla E, Prado CM. Cancerassociated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later. Proc Nutr Soc 2016; 75 (2): 199–211.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Tsoli M, Moore M, Burg D, Painter A, Taylor R, Lockie SH, Nigel Turner, Alessandra Warren, Greg Cooney, Brian Oldfild, Stephen Clarke, Graham Robertson. Activation of thermogenesis in brown adipose tissue and dysregulated lipid metabolism associated with cancer cachexia in mice. Cancer Res 2012; 72 (17): 4372–82.</mixed-citation><mixed-citation xml:lang="en">Tsoli M, Moore M, Burg D, Painter A, Taylor R, Lockie SH, Nigel Turner, Alessandra Warren, Greg Cooney, Brian Oldfild, Stephen Clarke, Graham Robertson. Activation of thermogenesis in brown adipose tissue and dysregulated lipid metabolism associated with cancer cachexia in mice. Cancer Res 2012; 72 (17): 4372–82.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">R. R. Echevarria, J. M. Barragan, M. P. Vargas, Davila-Rodriguez JR, Amezcua-Galvez E, Armendariz-Borunda J. Diet switch and omega-3 hydroxy-fatty acids display differential hepatoprotective effects in an obesity/nonalcoholic fatty liver disease model in mice. World J Gastroenterol. 2018 Jan 28; 24 (4): 461–474. DOI: 10.3748/wjg.v24.i4.461.</mixed-citation><mixed-citation xml:lang="en">R. R. Echevarria, J. M. Barragan, M. P. Vargas, Davila-Rodriguez JR, Amezcua-Galvez E, Armendariz-Borunda J. Diet switch and omega-3 hydroxy-fatty acids display differential hepatoprotective effects in an obesity/nonalcoholic fatty liver disease model in mice. World J Gastroenterol. 2018 Jan 28; 24 (4): 461–474. DOI: 10.3748/wjg.v24.i4.461.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer 2014; 14 (11): 754–62.</mixed-citation><mixed-citation xml:lang="en">Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer 2014; 14 (11): 754–62.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Fukawa T, Yan-Jiang BC, Min-Wen JC, Jun-Hao ET, Huang D, Qian CN, P. Ong, Z. Li, S. Chen, S. Y. Mak, W. Jun Lim, Hiro-Omi Kanayama, R. E. Mohan, R. R. Wang, J. H. Lai, C. Chua, Hock Soo Ong, Ker-Kan Tan, Ying Swan Ho, I. B. Tan, BT. Teh, Ng Shyh-Chang. Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia. Nat Med 2016; 22 (6): 666–71.</mixed-citation><mixed-citation xml:lang="en">Fukawa T, Yan-Jiang BC, Min-Wen JC, Jun-Hao ET, Huang D, Qian CN, P. Ong, Z. Li, S. Chen, S. Y. Mak, W. Jun Lim, Hiro-Omi Kanayama, R. E. Mohan, R. R. Wang, J. H. Lai, C. Chua, Hock Soo Ong, Ker-Kan Tan, Ying Swan Ho, I. B. Tan, BT. Teh, Ng Shyh-Chang. Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia. Nat Med 2016; 22 (6): 666–71.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Martinez-Outschoorn UE, Peiris-Pages M, Pestell RG, Sotgia F, Lisanti MP. Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol 2017; 14 (1): 11–31.</mixed-citation><mixed-citation xml:lang="en">Martinez-Outschoorn UE, Peiris-Pages M, Pestell RG, Sotgia F, Lisanti MP. Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol 2017; 14 (1): 11–31.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Lindor K. D. ; Fleming C. R. ; Abrams A.; Hirschkorn M. A. Liver function values in adults receiving total parenteral nutrition. JAMA 1979, 241, 2398–2400.</mixed-citation><mixed-citation xml:lang="en">Lindor K. D. ; Fleming C. R. ; Abrams A.; Hirschkorn M. A. Liver function values in adults receiving total parenteral nutrition. JAMA 1979, 241, 2398–2400.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Staun M.; Pironi, L.; Bozzetti, F.; Baxter, J.; Forbes, A.; Joly, F.; Jeppesen, P.; Moreno, J.; Hebuterne, X.; Pertkiewicz, M.; et al. Espen guidelines on parenteral nutrition: Home parenteral nutrition (HPN) in adult patients. Clin. Nutr. 2009, 28, 467–479.</mixed-citation><mixed-citation xml:lang="en">Staun M.; Pironi, L.; Bozzetti, F.; Baxter, J.; Forbes, A.; Joly, F.; Jeppesen, P.; Moreno, J.; Hebuterne, X.; Pertkiewicz, M.; et al. Espen guidelines on parenteral nutrition: Home parenteral nutrition (HPN) in adult patients. Clin. Nutr. 2009, 28, 467–479.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Gabe S.; Culkin A. Abnormal liver function tests in the parenteral nutrition fed patient. Frontline Gastroenterol. 2010, 1, 98–104.</mixed-citation><mixed-citation xml:lang="en">Gabe S.; Culkin A. Abnormal liver function tests in the parenteral nutrition fed patient. Frontline Gastroenterol. 2010, 1, 98–104.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Klek S.; Chambrier C.; Singer P.; Rubin M.; Bowling T.; Staun M.; Joly F.; Rasmussen H.; Strauss B. J.; Wanten G.; et al. Four-week parenteral nutrition using a third generation lipid emulsion (smoflpid) – A double-blind, randomised, multicentre study in adults. Clin. Nutr. 2013, 32, 224–231.</mixed-citation><mixed-citation xml:lang="en">Klek S.; Chambrier C.; Singer P.; Rubin M.; Bowling T.; Staun M.; Joly F.; Rasmussen H.; Strauss B. J.; Wanten G.; et al. Four-week parenteral nutrition using a third generation lipid emulsion (smoflpid) – A double-blind, randomised, multicentre study in adults. Clin. Nutr. 2013, 32, 224–231.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Goulet O.; Joly, F.; Corriol O.; Colomb-Jung V. Some new insights in intestinal failure-associated liver disease. Curr. Opin. Organ. Transplant. 2009, 14, 256–261.</mixed-citation><mixed-citation xml:lang="en">Goulet O.; Joly, F.; Corriol O.; Colomb-Jung V. Some new insights in intestinal failure-associated liver disease. Curr. Opin. Organ. Transplant. 2009, 14, 256–261.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Piper S. N.; Schade I.; Beschmann R. B.; Maleck W. H.; Boldt J.; Rohm K. D. Hepatocellular integrity after parenteral nutrition: Comparison of a fih-oil-containing lipid emulsion with an olive-soybean oil-based lipid emulsion. Eur. J. Anaesthesiol. 2009, 26, 1076–1082.</mixed-citation><mixed-citation xml:lang="en">Piper S. N.; Schade I.; Beschmann R. B.; Maleck W. H.; Boldt J.; Rohm K. D. Hepatocellular integrity after parenteral nutrition: Comparison of a fih-oil-containing lipid emulsion with an olive-soybean oil-based lipid emulsion. Eur. J. Anaesthesiol. 2009, 26, 1076–1082.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Tomsits E.; Pataki M.; Tolgyesi A.; Fekete G.; Rischak K.; Szollar L. Safety and effiacy of a lipid emulsion containing a mixture of soybean oil, medium-chain triglycerides, olive oil, and fih oil: A randomised, double-blind clinical trial in premature infants requiring parenteral nutrition. J. Pediatr. Gastroenterol. Nutr. 2010, 51, 514–521.</mixed-citation><mixed-citation xml:lang="en">Tomsits E.; Pataki M.; Tolgyesi A.; Fekete G.; Rischak K.; Szollar L. Safety and effiacy of a lipid emulsion containing a mixture of soybean oil, medium-chain triglycerides, olive oil, and fih oil: A randomised, double-blind clinical trial in premature infants requiring parenteral nutrition. J. Pediatr. Gastroenterol. Nutr. 2010, 51, 514–521.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">De Meijer V. E.; Gura K. M.; Meisel J. A.; Le H. D.; Puder M. Parenteral fih oil monotherapy in the management of patients with parenteral nutrition-associated liver disease. Arch. Surg. 2010, 145, 547–551.</mixed-citation><mixed-citation xml:lang="en">De Meijer V. E.; Gura K. M.; Meisel J. A.; Le H. D.; Puder M. Parenteral fih oil monotherapy in the management of patients with parenteral nutrition-associated liver disease. Arch. Surg. 2010, 145, 547–551.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Aleksova A, Masson S, Maggioni AP, D. Lucci, G. Fabbri, L. Beretta, L. Mos, A. M. Paino, G. L. Nicolosi, R. Marchioli, G. Tognoni, L. Tavazzi, G. Sinagra, R. Latini,. GISSI-Heart Failure investigators. n-3 polyunsaturated fatty acids and atrial firillation. Eur J Heart Fail, 2013, Nov; 15 (11): 1289–95.</mixed-citation><mixed-citation xml:lang="en">Aleksova A, Masson S, Maggioni AP, D. Lucci, G. Fabbri, L. Beretta, L. Mos, A. M. Paino, G. L. Nicolosi, R. Marchioli, G. Tognoni, L. Tavazzi, G. Sinagra, R. Latini,. GISSI-Heart Failure investigators. n-3 polyunsaturated fatty acids and atrial firillation. Eur J Heart Fail, 2013, Nov; 15 (11): 1289–95.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Allam-Ndoul B, Guénard F, Barbier O, Vohl MC. Effect of n-3 fatty acids on the ex-pression of inflmmatory genes in THP-1macrophages. Lipids Health Dis. 2016; 15: 69.</mixed-citation><mixed-citation xml:lang="en">Allam-Ndoul B, Guénard F, Barbier O, Vohl MC. Effect of n-3 fatty acids on the ex-pression of inflmmatory genes in THP-1macrophages. Lipids Health Dis. 2016; 15: 69.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Mayer K, Gokorsch S, Fegbeutel C, Hattar K, Rosseau S, Walmrath D, et al. Parenteral nutrition with fih oil modulates cytokine response in patients with sepsis. Am J Respir Crit Care Med. 2003; 167: 1321–8.</mixed-citation><mixed-citation xml:lang="en">Mayer K, Gokorsch S, Fegbeutel C, Hattar K, Rosseau S, Walmrath D, et al. Parenteral nutrition with fih oil modulates cytokine response in patients with sepsis. Am J Respir Crit Care Med. 2003; 167: 1321–8.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Singer P, Shapiro H, Theilla M, Anbar R, Singer J, Cohen J. Anti-inflmmatory properties of omega-3 fatty acids in critical illness: novel mechanisms and an integrative perspective. Intens Care Med. 2008; 34: 1580–92.</mixed-citation><mixed-citation xml:lang="en">Singer P, Shapiro H, Theilla M, Anbar R, Singer J, Cohen J. Anti-inflmmatory properties of omega-3 fatty acids in critical illness: novel mechanisms and an integrative perspective. Intens Care Med. 2008; 34: 1580–92.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Yang, P.; Jiang, Y.; Fischer, S. M. Prostaglandin E3 metabolism and cancer. Cancer Lett. 2014, 348, 1–11.</mixed-citation><mixed-citation xml:lang="en">Yang, P.; Jiang, Y.; Fischer, S. M. Prostaglandin E3 metabolism and cancer. Cancer Lett. 2014, 348, 1–11.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Tsuji, M.; Murota, S.I.; Morita, I. Docosapentaenoic acid (22:5, n-3) suppressed tube-forming activity in endothelial cells induced by vascular endothelial growth factor. Prostaglandins Leukot. Essent. Fatty Acids. 2003, 68, 337–342.</mixed-citation><mixed-citation xml:lang="en">Tsuji, M.; Murota, S.I.; Morita, I. Docosapentaenoic acid (22:5, n-3) suppressed tube-forming activity in endothelial cells induced by vascular endothelial growth factor. Prostaglandins Leukot. Essent. Fatty Acids. 2003, 68, 337–342.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Calviello G.; di Nicuolo F.; Gragnoli S.; Piccioni E.; Serini S.; Maggiano N.; Tringali G.; Navarra P.; Ranelletti F. O.; Palozza P. N-3 pufas reduce vegf expression in human colon cancer cells modulating the COX-2/PGE 2 induced ERK-1 and –2 and HIF-1alpha induction pathway. Carcinogenesis 2004, 25, 2303–2310.</mixed-citation><mixed-citation xml:lang="en">Calviello G.; di Nicuolo F.; Gragnoli S.; Piccioni E.; Serini S.; Maggiano N.; Tringali G.; Navarra P.; Ranelletti F. O.; Palozza P. N-3 pufas reduce vegf expression in human colon cancer cells modulating the COX-2/PGE 2 induced ERK-1 and –2 and HIF-1alpha induction pathway. Carcinogenesis 2004, 25, 2303–2310.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Arshad A.; Isherwood J.; Mann C.; Cooke J.; Pollard C.; Runau F.; Morgan B.; Steward W.; Metcalfe M.; Dennison A. Intravenous omega-3 fatty acids plus gemcitabine: Potential to improve response and quality of life in advanced pancreatic cancer. J. Parenter Enteral Nutr. 2015.</mixed-citation><mixed-citation xml:lang="en">Arshad A.; Isherwood J.; Mann C.; Cooke J.; Pollard C.; Runau F.; Morgan B.; Steward W.; Metcalfe M.; Dennison A. Intravenous omega-3 fatty acids plus gemcitabine: Potential to improve response and quality of life in advanced pancreatic cancer. J. Parenter Enteral Nutr. 2015.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Baracos V. E.; Mazurak V. C.; Ma D. W. N-3 polyunsaturated fatty acids throughout the cancer trajectory: Inflence on disease incidence, progression, response to therapy and cancer-associated cachexia. Nutr. Res. Rev. 2004, 17, 177–192.</mixed-citation><mixed-citation xml:lang="en">Baracos V. E.; Mazurak V. C.; Ma D. W. N-3 polyunsaturated fatty acids throughout the cancer trajectory: Inflence on disease incidence, progression, response to therapy and cancer-associated cachexia. Nutr. Res. Rev. 2004, 17, 177–192.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Sanchez-Lara K.; Turcott J. G.; Juarez-Hernandez E.; Nunez-Valencia C.; Villanueva G.; Guevara P.; de la Torre-Vallejo M.; Mohar A.; Arrieta O. Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: Randomised trial. Clin. Nutr. 2014, 33, 1017–1023.</mixed-citation><mixed-citation xml:lang="en">Sanchez-Lara K.; Turcott J. G.; Juarez-Hernandez E.; Nunez-Valencia C.; Villanueva G.; Guevara P.; de la Torre-Vallejo M.; Mohar A.; Arrieta O. Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: Randomised trial. Clin. Nutr. 2014, 33, 1017–1023.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Jann Arend, Patrick Bachmann, Vickie Baracos, Nicole Barthelemy, Hartmut Bertz at all. ESPEN guidelines on nutrition in cancer patients (2016). Clinical Nutrition xxx (2016) 1e+38.</mixed-citation><mixed-citation xml:lang="en">Jann Arend, Patrick Bachmann, Vickie Baracos, Nicole Barthelemy, Hartmut Bertz at all. ESPEN guidelines on nutrition in cancer patients (2016). Clinical Nutrition xxx (2016) 1e+38.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">van der Meij B. S.; Langius J. A.; Spreeuwenberg M. D.; Slootmaker S. M.; Paul M. A.; Smit E. F.; van Leeuwen P. A. Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: An RCT. Eur. J. Clin. Nutr. 2012, 66, 399–404.</mixed-citation><mixed-citation xml:lang="en">van der Meij B. S.; Langius J. A.; Spreeuwenberg M. D.; Slootmaker S. M.; Paul M. A.; Smit E. F.; van Leeuwen P. A. Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: An RCT. Eur. J. Clin. Nutr. 2012, 66, 399–404.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Trabal J.; Leyes P.; Forga M.; Maurel J. Potential usefulness of an EPA-enriched nutritional supplement on chemotherapy tolerability in cancer patients without overt malnutrition. Nutr. Hosp. 2010, 25, 736–740.</mixed-citation><mixed-citation xml:lang="en">Trabal J.; Leyes P.; Forga M.; Maurel J. Potential usefulness of an EPA-enriched nutritional supplement on chemotherapy tolerability in cancer patients without overt malnutrition. Nutr. Hosp. 2010, 25, 736–740.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Wang J.; Yu J. C.; Kang W. M.; Ma, Z. Q. Superiority of a fih oil-enriched emulsion to medium-chain triacylglycerols/long-chain triacylglycerols in gastrointestinal surgery patients: A randomized clinical trial. Nutrition 2012, 28, 623–629.</mixed-citation><mixed-citation xml:lang="en">Wang J.; Yu J. C.; Kang W. M.; Ma, Z. Q. Superiority of a fih oil-enriched emulsion to medium-chain triacylglycerols/long-chain triacylglycerols in gastrointestinal surgery patients: A randomized clinical trial. Nutrition 2012, 28, 623–629.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Han Y. Y.; Lai S. L.; Ko W. J.; Chou C. H.; Lai H. S. Effects of fih oil on inflmmatory modulation in surgical intensive care unit patients. Nutr. Clin. Pract. 2012, 27, 91–98.</mixed-citation><mixed-citation xml:lang="en">Han Y. Y.; Lai S. L.; Ko W. J.; Chou C. H.; Lai H. S. Effects of fih oil on inflmmatory modulation in surgical intensive care unit patients. Nutr. Clin. Pract. 2012, 27, 91–98.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">J iang Z. M .; Wilmore D. W.; Wang X. R.; Wei J . M .; Zhang Z. T.; Gu Z. Y.; Wang S.; Han S. M.; Jiang H.; Yu K. Randomized clinical trial of intravenous soybean oil alone versus soybean oil plus fish oil emulsion after gastrointestinal cancer surgery. Br. J. Surg. 2010, 97, 804–809.</mixed-citation><mixed-citation xml:lang="en">J iang Z. M .; Wilmore D. W.; Wang X. R.; Wei J . M .; Zhang Z. T.; Gu Z. Y.; Wang S.; Han S. M.; Jiang H.; Yu K. Randomized clinical trial of intravenous soybean oil alone versus soybean oil plus fish oil emulsion after gastrointestinal cancer surgery. Br. J. Surg. 2010, 97, 804–809.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">de Miranda Torrinhas R. S.; Santana R.; Garcia T.; Cury-Boaventura M.F.; Sales M. M.; Curi R.; Waitzberg D. L. Parenteral fih oil as a pharmacological agent to modulate post-operative immune response: A randomized, double-blind, and controlled clinical trial in patients with gastrointestinal cancer. Clin. Nutr. 2013, 32, 503–510.</mixed-citation><mixed-citation xml:lang="en">de Miranda Torrinhas R. S.; Santana R.; Garcia T.; Cury-Boaventura M.F.; Sales M. M.; Curi R.; Waitzberg D. L. Parenteral fih oil as a pharmacological agent to modulate post-operative immune response: A randomized, double-blind, and controlled clinical trial in patients with gastrointestinal cancer. Clin. Nutr. 2013, 32, 503–510.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu M. W.; Tang D. N.; Hou J.; Wei J. M.; Hua B.; Sun J. H.; Cui H. Y. Impact of fih oil enriched total parenteral nutrition on elderly patients after colorectal cancer surgery. Chin. Med. J. (Engl.) 2012, 125,178–181.</mixed-citation><mixed-citation xml:lang="en">Zhu M. W.; Tang D. N.; Hou J.; Wei J. M.; Hua B.; Sun J. H.; Cui H. Y. Impact of fih oil enriched total parenteral nutrition on elderly patients after colorectal cancer surgery. Chin. Med. J. (Engl.) 2012, 125,178–181.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu X.; Wu Y.; Qiu Y.; Jiang C.; Ding Y. Effects of omega-3 fih oil lipid emulsion combined with parenteral nutrition on patients undergoing liver transplantation. J. Parenter. Enteral Nutr. 2013, 37, 68–74.</mixed-citation><mixed-citation xml:lang="en">Zhu X.; Wu Y.; Qiu Y.; Jiang C.; Ding Y. Effects of omega-3 fih oil lipid emulsion combined with parenteral nutrition on patients undergoing liver transplantation. J. Parenter. Enteral Nutr. 2013, 37, 68–74.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Berger M. M.; Delodder F.; Liaudet L.; Tozzi P.; Schlaepfer J.; Chiolero R. L.; Tappy L. Three short perioperative infusions of n-3 pufas reduce systemic inflmmation induced by cardiopulmonary bypass surgery: A Randomized Controlled Trial. Am. J. Clin. Nutr. 2013, 97, 246–254.</mixed-citation><mixed-citation xml:lang="en">Berger M. M.; Delodder F.; Liaudet L.; Tozzi P.; Schlaepfer J.; Chiolero R. L.; Tappy L. Three short perioperative infusions of n-3 pufas reduce systemic inflmmation induced by cardiopulmonary bypass surgery: A Randomized Controlled Trial. Am. J. Clin. Nutr. 2013, 97, 246–254.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Klek S.; Waitzberg D. L. Intravenous lipids in adult surgical patients. In Intravenous Lipid Emulsions; Calder P. C., Waitzberg D. L., Koletzko B., Eds.; Karger: Basel, Switzerland, 2015; Volume 112, pp. 115–119.</mixed-citation><mixed-citation xml:lang="en">Klek S.; Waitzberg D. L. Intravenous lipids in adult surgical patients. In Intravenous Lipid Emulsions; Calder P. C., Waitzberg D. L., Koletzko B., Eds.; Karger: Basel, Switzerland, 2015; Volume 112, pp. 115–119.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Xue H.; Sawyer M. B.; Field C. J.; Dieleman L. A.; Baracos V. E. Nutritional modulation of antitumor effiacy and diarrhea toxicity related to irinotecan chemotherapy in rats bearing the ward colon tumor. Clin. Cancer Res. 2007, 13, 7146–7154.</mixed-citation><mixed-citation xml:lang="en">Xue H.; Sawyer M. B.; Field C. J.; Dieleman L. A.; Baracos V. E. Nutritional modulation of antitumor effiacy and diarrhea toxicity related to irinotecan chemotherapy in rats bearing the ward colon tumor. Clin. Cancer Res. 2007, 13, 7146–7154.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Xue H.; Ren W.; Denkinger M.; Schlotzer E.; Wischmeyer P. E. Nutrition modulation of cardiotoxicity and anticancer effiacy related to doxorubicin chemotherapy by glutamine and omega-3 polyunsaturated fatty acids. J. Parenter. Enteral Nutr. 2015.</mixed-citation><mixed-citation xml:lang="en">Xue H.; Ren W.; Denkinger M.; Schlotzer E.; Wischmeyer P. E. Nutrition modulation of cardiotoxicity and anticancer effiacy related to doxorubicin chemotherapy by glutamine and omega-3 polyunsaturated fatty acids. J. Parenter. Enteral Nutr. 2015.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Barber M. D. The pathophysiology and treatment of cancer cachexia. Nutr. Clin. Pract. 2002, 17, 203–209.</mixed-citation><mixed-citation xml:lang="en">Barber M. D. The pathophysiology and treatment of cancer cachexia. Nutr. Clin. Pract. 2002, 17, 203–209.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Calviello G.; Serini S.; Piccioni E. N-3 polyunsaturated fatty acids and the prevention of colorectal cancer: Molecular mechanisms involved. Curr. Med. Chem. 2007, 14, 3059–3069.</mixed-citation><mixed-citation xml:lang="en">Calviello G.; Serini S.; Piccioni E. N-3 polyunsaturated fatty acids and the prevention of colorectal cancer: Molecular mechanisms involved. Curr. Med. Chem. 2007, 14, 3059–3069.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Chang W. L.; Chapkin R. S.; Lupton J. R. Fish oil blocks azoxymethane-induced rat colon tumorigenesis by increasing cell differentiation and apoptosis rather than decreasing cell proliferation. J. Nutr. 1998, 128, 491–497.</mixed-citation><mixed-citation xml:lang="en">Chang W. L.; Chapkin R. S.; Lupton J. R. Fish oil blocks azoxymethane-induced rat colon tumorigenesis by increasing cell differentiation and apoptosis rather than decreasing cell proliferation. J. Nutr. 1998, 128, 491–497.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Tu WC, Muhlhausler BS, Yelland LN, Gibson RA. Correlations between blood and tissue omega-3 LCPUFA status following dietary ALA intervention in rats. Prostag Leukotr Ess. 2013; 88: 53–60.</mixed-citation><mixed-citation xml:lang="en">Tu WC, Muhlhausler BS, Yelland LN, Gibson RA. Correlations between blood and tissue omega-3 LCPUFA status following dietary ALA intervention in rats. Prostag Leukotr Ess. 2013; 88: 53–60.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Martin JM, Stapleton RD. Omega-3 fatty acids in critical illness. Nutr Rev. 2010; 68: 531–41.</mixed-citation><mixed-citation xml:lang="en">Martin JM, Stapleton RD. Omega-3 fatty acids in critical illness. Nutr Rev. 2010; 68: 531–41.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Wendel M.; Heller A. R. Anticancer actions of omega-3 fatty acids – Current state and future perspectives. Anticancer Agents Med. Chem. 2009, 9, 457–470.</mixed-citation><mixed-citation xml:lang="en">Wendel M.; Heller A. R. Anticancer actions of omega-3 fatty acids – Current state and future perspectives. Anticancer Agents Med. Chem. 2009, 9, 457–470.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
